CCL22 and neoplasm: The predominant chemokine receptor on human Treg is CCR4, the receptor for the chemokines CCL17 and CCL22 [1], which are produced by tumor cells, tumor- associated macrophages and dendritic cells, as well as by effector T cells (Teff) in the setting of an inflammatory anti-tumor response.